Clickmab AI Platform Supports Major APJ Collaboration Between Jikang Bio and BioAge

APJ and its ligand Apelin have emerged as important targets in metabolism and aging. As an exercise-induced factor, Apelin signaling influences metabolic balance, cardiovascular function, and aging-related pathways. Preclinical work suggests that APJ agonists can enhance GLP-1 driven weight loss, improve body composition, and restore muscle function, making them highly promising in obesity and broader metabolic disease indications.

GPCR targets are notoriously difficult, but Clickmab's AI platform provided critical support through deep structural analysis of GPCR activation, precise energy calculations, and iterative model optimization. Working from a known lead antibody, the platform guided multiple rounds of mutant design and screening. Some optimized variants achieved more than a 100-fold gain in agonist activity, with EC50 values reaching the picomolar range.

This APJ collaboration again validates Clickmab's advantages on complex targets, especially difficult classes such as GPCRs. Clickmab is focused on combining generative AI with large-scale experimental data to solve hard antibody discovery problems. The Click.mAb. platform supports efficient design across functional epitopes, low-immunogenicity epitopes, and highly homologous targets.